Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

Leukemia and Lymphoma

Volumn 47, Issue 1, 2006, Pages 29-37

  Bendandi, Maurizio ^a   Rodríguez Calvillo, Mercedes ^a   Inogés, Susana ^a   de Cerio, Ascensión López Díaz ^a   Pérez Simón, José Antonio ^b   Rodríguez Caballero, Arancha ^c   García Montero, Andres ^c   Almeida, Julia ^c   Zabalegui, Natalia ^a   Giraldo, Pilar ^d   San Miguel, Jesús ^b   Orfao, Alberto ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Allogeneic dendritic cells; Idiotype vaccine; Multiple myeloma

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RELAPSE; CASE REPORT; CELL ACTIVATION; CELL PROLIFERATION; CYTOKINE RELEASE; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATORY CELL; LYMPHOCYTE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; T LYMPHOCYTE; TH1 CELL;

CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN IDIOTYPES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE;

EID: 30844450344     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500272473     Document Type: Article

References (38)

1. Kyle, R and Rajkumar, S. (2004) Multiple myeloma New England Journal of Medicine, 351, pp. 1860-1873.
2. Cavo, M and Terragna, C and Martinelli, G and Ronconi, S and Zamagni, E and Tosi, P and (2000) Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for múltiple myeloma Blood, 96, pp. 355-357.
3. Martinelli, G and Terragna, C and Zamagni, E and Ronconi, S and Tosi, P and Lemoli, R and (2000) Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma Journal of Clinical Oncology, 18, pp. 2273-2281.
4. Bensinger, W and Buckner, C and Anasetti, C and Clift, R and Storb, R and Barnett, T and (1996) Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome Blood, 88, pp. 2787-2793.
5. Gahrton, G and Tura, S and Ljungmann and Belanger, C and Brandt, L and Cavo, M and (1991) Allogeneic bone marrow transplantation in multiple myeloma New England Journal of Medicine, 325, pp. 1267-1273.
6. Gahrton, G and Svensson, H and Cavo, M and Apperly, J and Bacigalupo, A and Bjorkstrand, B and (2001) Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-9193 and 1994-1998 at European Group for Blood and Marrow Transplantation center British Journal of Hematology, 113, pp. 209-216.
7. Kröger, N and Sayer, H and Schwerdtfeger, R and Kiehl, M and Nagler, A and Renges, H and (2002) Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation related mortality Blood, 100, pp. 3919-3924.
8. Maloney, D and Molina, A and Sahebi, F and Stockerl-Goldstein, K and Sandmaier, B and Bensinger, W and (2003) Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma Blood, 102, pp. 3447-3454.
9. Perez-Simon, J and Martino, R and Alegre, A and Tomas, J and De Leon, A and Caballero, D and (2003) Chronic but not acute Graft versus host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation British Journal of Haematology, 121, pp. 104-108.
10. Einsele, H and Schäfer, H and Hebart, H and Bader, P and Meisner, C and Plasswilm, L and (2003) Follow up of patients with progressive multiple myeloma undergoing allografts after reduced intensity conditioning British Journal of Haematology, 121, pp. 411-418.
11. Lynch, R and Graff, R and Sirisinha, S and Simms, E and Eisen, H. (1972) Myeloma proteins as tumor-specific transplantation antigens Proceedings of the National Academy of Sciences (USA), 69, pp. 1540-1544.
12. Bendandi, M. (2001) Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma Expert Reviews in Anticancer Therapy, 1, pp. 65-72.
13. Massaia, M and Borrione, P and Battaglio, S and Mariani, S and Beggiato, E and Napoli, P and (1999) Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy Blood, 94, pp. 673-683.
14. Osterborg, A and Yi, Q and Henriksson, L and Fagerberg, J and Bergenbrant, S and Jeddi-Tehrani, M and (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses Blood, 91, pp. 2459-2466.
15. Reichardt, V and Okada, C and Liso, A and Benike, C and Stockerl-Goldstein, K and Engleman, E and (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study Blood, 93, pp. 2411-2419.
16. Titzer, S and Christensen, O and Manzke, O and Tesch, H and Wolf, J and Emmerich, B and (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects British Journal of Haematology, 108, pp. 805-816.
17. Kwak, L and Campbell, M and Czerwinski, D and Hart, S and Miller, R and Levy, R. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors New England Journal of Medicine, 327, pp. 1209-1215.
18. Hsu, F and Caspar, C and Czerwinski, D and Kwak, L and Liles, T and Syrengelas, A and (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial Blood, 89, pp. 3129-3135.
19. Bendandi, M and Gocke, C and Kobrin, C and Benko, F and Sternas, L and Pennington, R and (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma Natural Medicine, 5, pp. 1171-1177.
20. Liso, A and Stockerl-Goldstein, K and Auffermann-Gretzinger, S and Benike, C and Reichardt, V and van Beckhoven, A and (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma Biology of Blood Marrow Transplant, 6, pp. 621-627.
21. Yi, Q and Desikan, R and Barlogie, B and Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma British Journal of Haematology, 117, pp. 297-305.
22. Reichardt, V and Milazzo, C and Brugger, W and Einsele, H and Kanz, L and Brossart, P. (2003) Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells Haematologica, 88, pp. 1139-1149.
23. Brown, R and Pope, B and Murray, A and Esdale, W and Sze, D and Gibson, J and (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10 Blood, 98, pp. 2992-2998.
24. Ratta, M and Fagnoni, F and Curti, A and Vescovini, R and Sansoni, P and Oliviero, B and (2002) Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6 Blood, 100, pp. 230-237.
25. Maas, F and Woestenenck, R and Zoetbrood, A and Levenga, H and Raymakers, R and de Witte, T and (2005) The role of dendritic cell genotype in the induction of T-cell responses against hematopoietic malignant cells after allogeneic stem cell transplantation Haematologica/ The Hematology Journal, 90 (s1), pp. 59.
26. Rodríguez-Caballero, A and García-Montero, A and Bueno, C and Almeida, J and Varro, R and Chen, R and (2004) A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation Laboratory Investigations, 84, pp. 1387-1398.
27. Bladé, J and Samson, D and Reece, D and Apperley, J and Bjorkstrand, B and Gahrton, G and (1998) Criteria for definition response relapse and progression in multiple myeloma after high-dose therapy British Journal of Haematology, 102, pp. 1115-1123.
28. Przepiorka, D and Weisdorf, D and Martin, P and Klingemann, H and Beatty, P and Hows, J and (1995) 1994 Consensus conference on acute GVHD grading Bone Marrow Transplantation, 15, pp. 825-828.
29. Sullivan, K and Shulman, H and Storb, R and Weiden, P and Witherspoon, R and McDonald, G and (1981) Chronic graft-versus- host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression Blood, 57, pp. 267-276.
30. Coscia, M and Mariani, S and Battaglio, S and Di Bello, C and Fiore, F and Foglietta, M and (2004) Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy Leukemia, 18, pp. 139-145.
31. Rasmussen, T and Hansson, L and Osterborg, A and Johnsen, H and Mellstedt, H. (2003) Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells Blood, 101, pp. 4607-4610.
32. Li, Y and Bendandi, M and Deng, Y and Dunbar, C and Munshi, N and Jagannath, S and (2000) Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells Blood, 96, pp. 2828-2832.
33. Nelson, E and Li, X and Hsu, F and Kwak, L and Levy, R and Clayberger, C and (1996) Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma Blood, 88, pp. 580-589.
34. Barrios, Y and Cabrera, R and Yanez, R and Briz, M and Plaza, A and Fores, R and (2002) Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma Haematologica, 87, pp. 400-407.
35. Weng, W and Czerwinski, D and Timmerman, J and Hsu, F and Levy, R. (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype Journal of Clinical Oncology, 22, pp. 4665-4672.
36. Kroger, N and Schilling, G and Einsele, H and Liebisch, P and Shimoni, A and Nagler, A and (2004) Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation Blood, 103, pp. 4056-4061.
37. Kroger, N and Perez-Simon, J and Myint, H and Klingemann, H and Shimoni, A and Nagler, A and (2004) Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma Biology of Blood Marrow Transplant, 10, pp. 698-708.
38. Banchereau, J and Palucka, A. (2005) Dendritic cells as therapeutic vaccines against cancer Natural Reviews in Immunology, 5, pp. 296-306.